PUBLISHER: Grand View Research | PRODUCT CODE: 1869910
PUBLISHER: Grand View Research | PRODUCT CODE: 1869910
The global smart syringes market size was estimated at USD 1.05 billion in 2024 and is projected to reach USD 2.22 billion by 2033, growing at a CAGR of 8.7% from 2025 to 2033. The growth is attributed to the increasing focus on patient and healthcare worker safety, particularly with the rise in Needle Stick Injuries (NSIs) and the transmission of blood-borne infections such as HIV and hepatitis.
Government-led vaccination drives and immunization initiatives, especially in countries such as India through the Universal Immunization Programme (UIP), have accelerated demand for auto-disable smart syringes. Moreover, regulatory bodies across the U.S. and Europe have mandated the use of safety-engineered injection devices, pushing healthcare facilities toward smart syringe adoption. Smart syringes have safety-engineered features such as retractable needles or auto-disable mechanisms, significantly reducing the risk of accidental needle-stick injuries. This has become a major public health priority, especially among healthcare workers in hospitals and clinics. For Instance, according to a report by International Journal of Surgery Global Health in 2024, Needlestick injuries (NSIs) are predominantly reported in medical and surgical departments, accounting for over 50% of all incidents.
High-risk areas include trauma and emergency rooms (38%) and operating rooms (3%). Among the key products contributing to NSIs, insulin administration in diabetic patients is a significant cause. Healthcare professionals such as emergency personnel, surgeons, and nurses are particularly at risk. Globally, the prevalence of NSIs is estimated at 42.8% among nurses, 46.4% among doctors, and 45.3% among nursing students. In general, NSI rates among nurses are approximately 41%, while nursing student rates vary widely from 8.7% to 71%.
Global initiatives aimed at expanding immunization coverage, particularly in developing regions, are significantly boosting the demand for auto-disable smart syringes. These syringes are designed for single use, effectively preventing reuse and enhancing vaccine safety. In India, the Universal Immunization Programme (UIP) is one of the largest public health efforts, reaching approximately 26.7 million newborns and 29 million pregnant women annually. Recognized as one of the most cost-effective health interventions, the UIP has significantly reduced under-five mortality rates caused by vaccine-preventable diseases.
The rising incidence of blood-borne infections such as HIV, hepatitis B (HBV), and hepatitis C (HCV) is a major driver for the smart syringe market. Unsafe injection practices, including the reuse of syringes and needles, are significant contributors to the spread of these infections, especially in developing and resource-limited healthcare settings. Smart syringes, including auto-disable and safety-engineered models, are designed to prevent reuse and accidental needlestick injuries, thereby playing a critical role in reducing transmission risks.
Global Smart Syringes Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global smart syringes market report based on product, application, distribution channel, technology, and region: